Zhifei Bio's 15-valent pneumococcal vaccine application accepted

Chongqing Zhifei Biological Products Co., Ltd. [SZSE:300122] announced that its subsidiary, Zhifei Green Bamboo Pharmaceutical Co., Ltd., has received notification that its application for production registration of its 15-valent pneumococcal conjugate vaccine has been accepted. The vaccine is designed to prevent diseases caused by the 15 most prevalent pneumococcal serotypes in Asia, aligning with domestic serotype distribution. According to the announcement, this multivalent vaccine reflects Zhifei's commitment to innovation and addresses a critical public health need, as pneumococcal infections remain a leading cause of lower respiratory infections and mortality worldwide, with estimates of 97.9 million cases and 500,000 deaths in 2021 alone. While this acceptance will not have a significant impact on the company's immediate financial results, successful registration and commercialization are expected to positively contribute to Zhifei's future growth and strengthen its position in the pneumococcal vaccine market, complementing its existing 23-valent pneumococcal polysaccharide vaccine and its 26-valent pneumococcal conjugate vaccine currently in clinical trials.